Table 1.
Main characteristics of patients and treatment plan.
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | |
| Patient | Male, 12 y.o. | Female, 8 y.o. | Female, 5 y.o. | Female, 13 y.o. | Female, 8 y.o. |
| Diagnosis | Ewing Sarcoma extraosseous, intrathoracic | Rhabdomyosarcoma mediastinum, stage III | Metastasis of base of skull with bone, para-nasal and lef eye infiltration from Nefroblastoma of right kidney | Rhabdomyosarcoma anus. Metastasis lymphnodes intrapelvic, inguinal and osseous |
Wilm's tumour of the left kidney. (Multiple lung metastasis). Multiple liver metastasis |
| Status | After chemotherapy + surgery + chemotherapy | After chemotherapy | After chemotherapy + right nefrectomy | After chemotherapy | After chemotherapy + left nefrectomy + chemo-radiotherapy for lung metastasis |
|
Radiotherapy dose Prescription |
PTV = 28 × 1.9 = 53.2 Gy PTV scar = 28 × 1.6 = 44.8 Gy |
PTVII = 25 × 1.98 = 49.5 Gy PTVI = 25 × 1.80 = 45.0 Gy |
PTVII = 17 × 2.5 = 42.5 Gy PTVI = 17 × 1.8 = 30.6 Gy |
PTVII = 25 × 1.98 = 49.5 Gy PTVI = 25 × 1.80 = 45 Gy |
PTV = 15 × 1.2 18 Gy |
| Target volumes | PTV = 564 cm3 PTV scar = 14 cm3 |
PTVI = 109 cm3 PTVII = 72 cm3 |
PTVI = 1436 cm3 PTVII = 104 cm3 |
PTVI = 618 cm3 PTVII = 193 cm3 |
PTV = 1234 cm3 |
| Organs at risk dose objectives | Lung1 < 15 Gy Heart1 < 30 Gy Vertebra1 < 20 Gy Spinal cord2 < 45 Gy |
Lung1 < 15 Gy Heart1 < 30 Gy Vertebra1 < 20 Gy Spinal cord2 < 45 Gy |
Right eye1 < 40 Gy Left eye (blind)1 < 50 Gy Lens1 < 10 Gy Spinal cord2 < 45 Gy |
Rectum1 < 40 Gy Bladder1 < 30 Gy Uterus1 < 20 Gy Femural heads1 < 20 Gy |
Kidney1 < 10 Gy |
| Techniques | RA: 2 copl arcs, HDMLC HT: Fld s. 2.5 cm, pitch 0.43 IMP: 3 fields |
RA: 2 copl arcs, HDMLC HT: Fld s. 2.5 cm, pitch 0.43 IMP: 2 fields |
RA: 2 copl arcs, MLC120 HT: Fld s. 2.5 cm, pitch 0.43 IMP: 2 fields |
RA: 2 non copl arcs, MLC120 HT: Fld s. 2.5 cm, pitch 0.43 IMP: 6 fields |
RA: 2 non copl arcs, MLC120 HT: Fld s. 2.5 cm, pitch 0.43 IMP: 2 fields |
|
Delivery time MU |
RA: 129 s, MU: 479 HT: 387 s MU: NA IMP: NA MU: NA |
RA: 123 s MU: 370 HT: 146 s MU: NA IMP: NA MU: NA |
RA: 129 s MU: 538 HT: 341 s MU: NA IMP: NA MU: NA |
RA: 127 s MU: 527 HT: 334 s MU: NA IMP: NA MU: NA |
RA: 129 s MU: 483 HT: 255 s MU: NA IMP: NA MU: NA |
1: mean dose; 2: maximum dose